Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
Yin-Feng Kang, Cong Sun, Zhen Zhuang, Run-Yu Yuan, Qingbing Zheng, Jiang-Ping Li, Ping-Ping Zhou, Xin-Chun Chen, Zhe Liu, Xiao Zhang, Xiaohui Yu, Xiang-Wei Kong, Qian-Ying Zhu, Qian Zhong, Miao Xu, Nanshan Zhong, Yi-Xin Zeng, Guo‐Kai Feng, Changwen Ke, Jin-cun Zhao, Mu‐Sheng Zeng
Abstract
, further corroborating the promising immunization effect. Additionally, the vaccine has distinct advantages in terms of a relatively simple scale-up and flexible assembly. These results illustrate that the SARS-CoV-2 RBD-conjugated nanoparticles developed in this study are a competitive vaccine candidate and that the carrier nanoparticles could be adopted as a universal platform for a future vaccine development.
Topics & Concepts
Spike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Spike (software development)Virology2019-20 coronavirus outbreakCoronavirusNanotechnologyNanoparticleMaterials scienceMedicineComputer scienceInfectious disease (medical specialty)DiseaseOutbreakPathologySoftware engineeringSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches